ArticleHealth science reports2026
Diagnostic Value of Neutrophil-to-Lymphocyte Ratio and Mean Platelet Volume as Predictors of Liver Fibrosis Severity in MASLD: A Cross-Sectional Study.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) has become a leading cause of chronic liver disease worldwide, yet simple and reliable non-invasive markers for fibrosis assessment remain limited. Accessible blood-based indicators could aid early detection of significant fibrosis. This cross-sectional study evaluated the diagnostic performance of neutrophil-to-lymphocyte ratio (NLR) and mean platelet volume (MPV) as non-invasive predictors of liver fibrosis severity in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Methods: This cross-sectional study analyzed data extracted from medical records collected between 2020 and 2023. MASLD diagnosis was based on clinical, laboratory, and imaging findings. Liver fibrosis stage was assessed using transient elastography. Statistical analyses included comparative tests between fibrosis groups and ROC curve analysis to identify optimal cut-off values and evaluate diagnostic performance. Results: A total of 140 patients were included. Patients were divided into two groups: non-significant fibrosis (F < F2; Conclusion: NLR and MPV correlate significantly with fibrosis severity and may serve as accessible, low-cost adjunctive biomarkers for early risk stratification of MASLD patients, especially in primary care or resource-limited settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.